



(12) Translation of
European patent specification

(11) NO/EP 3494116 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 471/04 (2006.01)
A61K 31/437 (2006.01)
A61K 31/501 (2006.01)
A61K 31/506 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.02.24
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.10.23
(86)	European Application Nr.	18705097.6
(86)	European Filing Date	2018.01.29
(87)	The European Application's Publication Date	2019.06.12
(30)	Priority	2017.01.30, US, 201762451971 P 2017.06.22, US, 201762523695 P 2017.09.19, US, 201762560304 P 2017.11.30, US, 201762592485 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated Validation States:	MA; MD; TN
(73)	Proprietor	Astrazeneca AB, 151 85 Södertälje, Sverige
(72)	Inventor	SCOTT, James, Stewart, AstraZeneca, Darwin BuildingCambridge Science ParkMilton Road, Cambridgeshire CB4 0WG, Storbritannia MOSS, Thomas, Andrew, AstraZeneca,Darwin Building, Cambridge Science ParkMilton Road,, Cambridgeshire CB4 0WG, Storbritannia HUGHES, Samantha, Jayne, AstraZeneca,Darwin Building, Cambridge Science ParkMilton Road, Cambridge, Cambridgeshire CB4 0WG, Storbritannia NISSINK, Johannes, Wilhelmus, Maria, AstraZenecaDarwin Building, Cambridge Science ParkMilton Road, Cambridge, Cambridgeshire CB4 0WG, Storbritannia BARLAAM, Bernard, Christophe, AstraZeneca,Darwin Building, Cambridge Science ParkMilton Road, Cambridge, Cambridgeshire CB4 0WG, Storbritannia YANG, Bin, AstraZeneca,35 Gatehouse Drive, Waltham, MA 02451, USA
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **ESTROGEN RECEPTOR MODULATORS**


(56) References

Cited: US-A1- 2014 357 661
US-A1- 2016 175 289
US-A1- 2012 157 402
US-A1- 2018 021 316

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. (R)-3-((1R,3R)-1-(5-fluor-2-(2-((3-fluorpropyl)amino)etoksy)-3-metylpyridin-4-yl)-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-metylpropansyre,




5

eller et farmasøytisk akseptabelt salt derav.

2. Forbindelsen ifølge krav 1 som er (R)-3-((1R,3R)-1-(5-fluor-2-(2-((3-fluorpropyl)amino)etoksy)-3-metylpyridin-4-yl)-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-metylpropansyre,

10



3. Farmasøytisk sammensetning omfattende forbindelsen ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, og en farmasøytisk akseptabel eksipiens.

15

4. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge krav 1, for anvendelse som et medikament.

5. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge krav 1, for anvendelse i forebygging eller behandling av kreft hos et varmblodig dyr.

20

6. Forbindelse, eller et farmasøytisk akseptabelt salt derav, for anvendelse ifølge krav 5, hvori kreften er brystkreft eller gynecologisk kreft.